Commerce.gov is getting a facelift soon. See the new design.

Intellectual Property Key to Protecting Pharma and Biotech Innovation

Printer-friendly version
Intellectual Property Key to Protecting Pharma and Biotech Innovation

Did you know the U.S. Patent and Trademark Office plays an important role in getting biotechnology and pharmaceutical products to market? Biotech and pharma are major areas of patenting for the USPTO. In fact, since 2009, the USPTO granted more than 31,000 patents in the “Molecular Biology and Microbiology” classification, and about 30,000 in the “Drug, Bio-Affecting and Body Treating Compositions” classification. There has also been a significant increase in recent years in patents granted for medical devices. In 2012, the USPTO granted more than 16,000 patents in that category, a 157 percent increase in five years. 

On Wednesday June 25, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO Michelle K. Lee spoke at the BIO International Convention in San Diego, California on the importance of patents in the pharmaceutical and biotech industries. Read Deputy Director Lee’s speech. 

“When you do find that one-in-a-hundred success—that drug that truly works—it’s critical that you have the patent protection necessary to get that drug to market and recoup your investment on the 99 attempts that didn’t succeed,” said Lee. 

The importance of intellectual property in innovation is exemplified through the pioneers and patent holders who were recently inducted into the National Inventors Hall of Fame, a program managed by the USPTO in partnership with the non-profit Invent Now. 

One of these inductees, Dr. Richard DiMarchi,has received international recognition for the discovery of peptide-based polypharmacy directed at the treatment of diabetes and obesity. He received a patent for Insulin LisPro, better known by its trademarked name, Humalog®, which is currently used daily by more than a million patients with Type 2 diabetes. Dr. DiMarchi continues to engage in research, and recently said that one of his unachieved goals is to focus on a disease like Alzheimer’s, reduce it to a molecular target, and then design a drug that will work in human clinical studies. 

Strong intellectual property is key to protecting innovation in the biotech and pharmaceutical industries, and the USPTO continues to work on the White House executive actions to issue the highest quality patents possible, add transparency to our patent system, and level the playing field for all players. 

Post new comment

(If you're a human, don't change the following field)
Your first name.
Comment Policy

To ensure that everyone can participate in polite conversation, these comments may be moderated. For detailed information on how and what we moderate, view our comment policy.

CAPTCHA
This question tests whether you are a human visitor and prevents automated spam submissions.
4 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.